These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20801117)

  • 1. The role of Pvs28 in sporozoite development in Anopheles sinensis and its longevity in BALB/c mice.
    Kim TS; Kim HH; Moon SU; Lee SS; Shin EH; Oh CM; Kang YJ; Kim DK; Sohn Y; Kim H; Lee HW
    Exp Parasitol; 2011 Feb; 127(2):346-50. PubMed ID: 20801117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates.
    Sattabongkot J; Tsuboi T; Hisaeda H; Tachibana M; Suwanabun N; Rungruang T; Cao YM; Stowers AW; Sirichaisinthop J; Coleman RE; Torii M
    Am J Trop Med Hyg; 2003 Nov; 69(5):536-41. PubMed ID: 14695092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking effect of a monoclonal antibody against recombinant Pvs25 on sporozoite development in Anopheles sinensis.
    Moon SU; Kim HH; Kim TS; Choi KM; Oh CM; Ahn YJ; Hwang SK; Sohn Y; Shin EH; Kim H; Lee HW
    Clin Vaccine Immunol; 2010 Aug; 17(8):1183-7. PubMed ID: 20554802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission.
    Blagborough AM; Yoshida S; Sattabongkot J; Tsuboi T; Sinden RE
    Vaccine; 2010 Aug; 28(37):6014-20. PubMed ID: 20637303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequence variation of ookinete surface proteins Pvs25 and Pvs28 of Plasmodium vivax isolates from Southern Mexico and their association to local anophelines infectivity.
    González-Cerón L; Alvarado-Delgado A; Martínez-Barnetche J; Rodríguez MH; Ovilla-Muñoz M; Pérez F; Hernandez-Avila JE; Sandoval MA; Rodríguez Mdel C; Villarreal-Treviño C
    Infect Genet Evol; 2010 Jul; 10(5):645-54. PubMed ID: 20363376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmodium vivax: a monoclonal antibody recognizes a circumsporozoite protein precursor on the sporozoite surface.
    Gonzalez-Ceron L; Rodriguez MH; Wirtz RA; Sina BJ; Palomeque OL; Nettel JA; Tsutsumi V
    Exp Parasitol; 1998 Nov; 90(3):203-11. PubMed ID: 9806864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant Pvs48/45 antigen expressed in E. coli generates antibodies that block malaria transmission in Anopheles albimanus mosquitoes.
    Arévalo-Herrera M; Vallejo AF; Rubiano K; Solarte Y; Marin C; Castellanos A; Céspedes N; Herrera S
    PLoS One; 2015; 10(3):e0119335. PubMed ID: 25775466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
    Devi YS; Mukherjee P; Yazdani SS; Shakri AR; Mazumdar S; Pandey S; Chitnis CE; Chauhan VS
    Vaccine; 2007 Jul; 25(28):5166-74. PubMed ID: 17544179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmodium vivax gametocyte protein Pvs230 is a transmission-blocking vaccine candidate.
    Tachibana M; Sato C; Otsuki H; Sattabongkot J; Kaneko O; Torii M; Tsuboi T
    Vaccine; 2012 Feb; 30(10):1807-12. PubMed ID: 22245309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The surface protein Pvs25 of Plasmodium vivax ookinetes interacts with calreticulin on the midgut apical surface of the malaria vector Anopheles albimanus.
    Rodríguez Mdel C; Martínez-Barnetche J; Alvarado-Delgado A; Batista C; Argotte-Ramos RS; Hernández-Martínez S; González Cerón L; Torres JA; Margos G; Rodríguez MH
    Mol Biochem Parasitol; 2007 Jun; 153(2):167-77. PubMed ID: 17442413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic diversity of transmission blocking vaccine candidate (Pvs25 and Pvs28) antigen in Plasmodium vivax clinical isolates from Iran.
    Zakeri S; Razavi S; Djadid ND
    Acta Trop; 2009 Mar; 109(3):176-80. PubMed ID: 18950597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials.
    Ramjanee S; Robertson JS; Franke-Fayard B; Sinha R; Waters AP; Janse CJ; Wu Y; Blagborough AM; Saul A; Sinden RE
    Vaccine; 2007 Jan; 25(5):886-94. PubMed ID: 17049690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine.
    Miyata T; Harakuni T; Sugawa H; Sattabongkot J; Kato A; Tachibana M; Torii M; Tsuboi T; Arakawa T
    Vaccine; 2011 Mar; 29(15):2720-6. PubMed ID: 21315699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates.
    Tsuboi T; Kaslow DC; Gozar MM; Tachibana M; Cao YM; Torii M
    Mol Med; 1998 Dec; 4(12):772-82. PubMed ID: 9990863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody response of naturally infected individuals to recombinant Plasmodium vivax apical membrane antigen-1.
    Rodrigues MH; Rodrigues KM; Oliveira TR; Cômodo AN; Rodrigues MM; Kocken CH; Thomas AW; Soares IS
    Int J Parasitol; 2005 Feb; 35(2):185-92. PubMed ID: 15710439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies to Plasmodium vivax transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 do not show synergism.
    Hisaeda H; Collins WE; Saul A; Stowers AW
    Vaccine; 2001 Dec; 20(5-6):763-70. PubMed ID: 11738740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent immunogenicity of DNA vaccines encoding Plasmodium vivax transmission-blocking vaccine candidates Pvs25 and Pvs28-evaluation of homologous and heterologous antigen-delivery prime-boost strategy.
    Kongkasuriyachai D; Bartels-Andrews L; Stowers A; Collins WE; Sullivan J; Sattabongkot J; Torii M; Tsuboi T; Kumar N
    Vaccine; 2004 Aug; 22(23-24):3205-13. PubMed ID: 15297075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies to malaria vaccine candidates Pvs25 and Pvs28 completely block the ability of Plasmodium vivax to infect mosquitoes.
    Hisaeda H; Stowers AW; Tsuboi T; Collins WE; Sattabongkot JS; Suwanabun N; Torii M; Kaslow DC
    Infect Immun; 2000 Dec; 68(12):6618-23. PubMed ID: 11083773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasmodium vivax gametocyte proteins, Pvs48/45 and Pvs47, induce transmission-reducing antibodies by DNA immunization.
    Tachibana M; Suwanabun N; Kaneko O; Iriko H; Otsuki H; Sattabongkot J; Kaneko A; Herrera S; Torii M; Tsuboi T
    Vaccine; 2015 Apr; 33(16):1901-8. PubMed ID: 25765968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cloning, expression and transmission-blocking activity of anti-PvWARP, malaria vaccine candidate, in Anopheles stephensi mysorensis.
    Gholizadeh S; Basseri HR; Zakeri S; Ladoni H; Djadid ND
    Malar J; 2010 Jun; 9():158. PubMed ID: 20537198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.